The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

被引：0

作者：

Giai, Valentina ^{[1
]}

Stagno, Fabio ^{[2
]}

Rosso, Tiziana ^{[3
,4
]}

Castagnetti, Fausto ^{[5
,6
]}

Capodanno, Isabella ^{[7
]}

Bonifacio, Massimiliano ^{[8
,9
]}

Tiribelli, Mario ^{[10
]}

Galimberti, Sara ^{[11
]}

Bocchia, Monica ^{[12
]}

Gozzini, Antonella ^{[13
]}

Caocci, Giovanni ^{[14
]}

Patriarca, Andrea ^{[15
]}

Lanzarone, Giuseppe ^{[16
]}

Guella, Anna ^{[17
]}

Sora, Federica ^{[18
]}

Luciano, Luigiana ^{[19
]}

Scortechini, Anna Rita ^{[20
]}

di Renzo, Nicola ^{[21
]}

Musto, Pellegrino ^{[22
,23
]}

Pastore, Domenico ^{[24
]}

Maggi, Alessandro ^{[25
]}

Fava, Carmen ^{[26
,27
]}

Pavone, Vincenzo

Fozza, Claudio ^{[28
,29
]}

Spinosa, Giuseppina ^{[30
]}

Carella, Angelo Michele ^{[31
]}

Tarantini, Giuseppe ^{[32
]}

Martino, Bruno ^{[33
]}

Pizzuti, Michele ^{[34
]}

Mannarella, Clara ^{[35
]}

Saccona, Fabio

Rosti, Gianantonio ^{[36
]}

Pregno, Patrizia ^{[37
]}

Breccia, Massimo ^{[38
]}

Pane, Fabrizio ^{[3
,4
,39
]}

Ciccone, Giovannino ^{[40
,41
]}

Specchia, Giorgina ^{[42
]}

Saglio, Giuseppe ^{[43
]}

机构：

[1] Citta Salute Sci, Div Hematol, Turin, Italy

[2] AOU Policlin Rodolico San Marco, Div Hematol & Bone Marrow Transplant, Catania, Italy

[3] Citta Salute Sci, Clin Epidemiol Unit, Turin, Italy

[4] Citta Salute Sci, CPO Piemonte, Turin, Italy

[5] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[6] IRCCS Azienda Osped Univ Bologna, Hematol Unit, Bologna, Italy

[7] Azienda Unita Sanitaria Locale IRCCS, Hematol Unit, Reggio Emilia, Italy

[8] Azienda Osped Univ Integrata Verona, Dept Med, Verona, Italy

[9] Univ Verona, Sect Innovat Biomed, Dept Engn Innovat Med, Hematol Area, Verona, Italy

[10] Univ Udine, Div Hematol & BMT, Dept Med Area, Udine, Italy

[11] Univ Pisa, Dept Clin & Expt Med, Hematol, Pisa, Italy

[12] Univ Siena, Azienda Osped Univ Senese, Hematol, Siena, Italy

[13] Univ Florence, Hematol, AOU Careggi, Florence, Italy

[14] Univ Cagliari, Businco Hosp, Dept Med Sci & Publ Hlth, Cagliari, Italy

[15] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[16] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[17] APSS Trento, Santa Chiara Hosp, Hematol Unit, Trento, Italy

[18] Univ Cattolica Sacro Cuore, Inst Hematol, Rome, Italy

[19] Univ Naples Federico II, Hematol Unit, Naples, Italy

[20] Polytech Univ Marche, Div Hematol, Dept Mol & Clin Sci, Ancona, Italy

[21] Osped V Fazzi, Haematol, Lecce, Italy

[22] Aldo Moro Univ, Sch Med, Dept Precis & Regenerat Med & Ionian Area, Haematl, Bari, Italy

[23] AOU Consorziale Policlin, Hematol & Stem Cell Transplantat Unit, Bari, Italy

[24] Osped A Perrino, Haematol, Brindisi, Italy

[25] Osped SG Moscati, Haematol, Taranto, Italy

[26] Mauriziano Hosp, Hematol, Turin, Italy

[27] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[28] Azienda C Panico, Hematol Unit, Tricase, Italy

[29] Univ Sassari, Azienda Osped Univ Sassari, Hematol Unit, Sassari, Italy

[30] Policlin Riuniti Osped Univ, Hematol Unit, Foggia, Italy

[31] IRCCS Casa Sollievo Sofferenza, Hematol Unit, San Giovanni Rotondo, Italy

[32] Osped Mons Dimiccoli, Haematol, Barletta, Italy

[33] Grande Osped Metropolitano Bianchi Melacrino More, Hematol Unit, Reggio Di Calabria, Italy

[34] San Carlo Reg Hosp, Dept Oncohematol, Potenza, Italy

[35] Osped Madonna Grazie, Hematol Unit, Matera, Italy

[36] IRST IRCCS Dino Amadori, Med Oncol Unit, Meldola, FC, Italy

[37] Citta Salute Sci, Div Hematol, Turin, Italy

[38] Hematol Sapienza Univ, Dept Translat & Precis Med, Rome, Italy

[39] Azienda Osped Univ Federico II, Dipartimento Med Clin & Chirurgia, UOC Ematol & Trapianti Midollo, Naples, Italy

[40] AOU Citta Salute & Sci, SSD Epidemiol Clin & Valutativa, Turin, Italy

[41] CPO Piemonte, Turin, Italy

[42] Univ Bari, Hematol, Bari, Italy

[43] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182981

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 36 条

[21] Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs
Hochhaus, Andreas
Boquimpani, Carla
Rea, Delphine
Minami, Yosuke
Lomaia, Elza
Voloshin, Sergey
Turkina, Anna G.
Kim, Dong-Wook
Apperley, Jane
Cortes, Jorge E.
Abdo, Andre
Fogliatto, Laura Maria
Kim, Dennis Dong Hwan
Le Coutre, Philipp D.
Saussele, Susanne
Annunziata, Mario
Hughes, Timothy P.
Chaudhri, Naeem A.
Chee, Lynette C. Y.
Gutierrez, Valentin Garcia
Sasaki, Koji
Aimone, Paola
Allepuz, Alex
Quenet, Sarah
Bedoucha, Veronique
Mauro, Michael J.
BLOOD, 2020, 136
[22] A first community-based, observational study on panitumumab as 1st and 2nd line combination therapy of metastatic colorectal cancer (mCRC) in RAS wildtype patients
Hebart, H.
Tessen, H. W.
Linde, H.
Koukakis, R.
Rieth, A.
Hellebrand, E.
Reichert, D.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 73 - 73
[23] The impact of TP53 mutations on EGFR mt plus NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy - Real world data from the German CRISP registry
Roeper, J.
Heukamp, L.
Falk, M.
Tiemann, M.
Stenzinger, A.
Thomas, M.
Christopoulos, P.
Griesinger, F.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 135 - 136
[24] OPTIS2: A Second Generation Horizontal Beam Line for Ocular Proton Therapy using a 250 MeV Cyclotron - First Patients Treated 25 Years after Start of the OPTIS Program at Paul Scherrer Institute
Verwey, J.
Assenmacher, F.
Heufelder, J.
van Goethem, M.
Grossmann, M.
Goitein, G.
Lomax, T.
Tourovsky, A.
Zografos, L.
Hug, E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S132 - S133
[25] Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study
Su, Yi-Jiun
Kuo, Ming-Chung
Teng, Chieh-Lin
Chen, Tsai-Yun
Ma, Ming-Chun
Hsiao, Pei-Ching
Wang, Ming-Chung
Lin, Tung-Huei
Hwang, Wen-Li
Chen, Chih-Cheng
Yang, Youngsen
Pei, Sung-Nan
Huang, Yen-Min
Li, Sin-Syue
Lee, Ming-Yang
Cheng, Hung-I
Shih, Lee-Yung
BLOOD, 2017, 130
[26] CA180-034 final study results: Seven-year (yr) follow-up of chronic-phase chronic myeloid leukemia (CML-CP) patients (pts) with imatinib resistance or -intolerance receiving dasatinib, a 2nd-generation BCR-ABL tyrosine kinase inhibitor (TKI)
Mueller, M. C.
Shah, N. P.
Rousselot, P.
Schiffer, C.
Rea, D.
Cortes, J.
Mohamed, H.
Healey, D.
Kantarjian, H.
Hochhaus, A.
Saglio, G.
Oncology Research and Treatment, 2015, 38 : 23 - 23
[27] The impact of TP53 mutations on EGFR mt plus NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy: Real-world data from two certified lung cancer centers in Germany
Roeper, J.
Christopoulos, P.
Falk, M.
Heukamp, L. C.
Stenzinger, A.
Thomas, M.
Griesinger, F.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S772 - S773
[28] Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
Hsu, Ping-Chih
Huang, Chun-Yao
Lin, Yu-Ching
Lee, Suey-Haur
Chiu, Li-Chung
Wu, Chiao-En
Kuo, Scott Chih-Hsi
Ju, Jia-Shiuan
Huang, Allen Chung-Cheng
Ko, Ho-Wen
Wang, Chin-Chou
Yang, Cheng-Ta
FRONTIERS IN ONCOLOGY, 2023, 13
[29] HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
Carlino, Francesca
Diana, Anna
Ventriglia, Anna
Piccolo, Antonio
Mocerino, Carmela
Riccardi, Ferdinando
Bilancia, Domenico
Giotta, Francesco
Antoniol, Giulio
Famiglietti, Vincenzo
Feliciano, Salvatore
Cangiano, Rodolfo
Lobianco, Lorenzo
Pellegrino, Benedetta
De Vita, Ferdinando
Ciardiello, Fortunato
Orditura, Michele
CANCERS, 2022, 14 (20)
[30] Two-year follow up results of a population-based prospective case control study of 143 stage IV colorectal cancer (CRC) patients treated with 2nd line irinotecan (iri) outside of clinical trial.
Lang, I
Hitre, E
Horvath, Z
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S

← 1 2 3 4 →